← Back to Home

Making CAR-T Directly in the Body: CD22 Therapy UB-VV400 Cleared to Begin US Trial

Umoja is bypassing ex vivo collection and manufacturing, attempting to generate CAR-T cells inside patients using a lentiviral vector; the FDA-cleared early-stage trial will first address safety, dosing, and technical feasibility.

By SURL BioNews

Current autologous CAR-T treatments require T cells to first be collected from the patient, genetically modified and expanded in a factory, and then returned to the hospital for infusion. This process has produced deep remissions in multiple blood cancers, but it also comes with challenges including waiting times, manufacturing failures, and treatment accessibility. Umoja Biopharma has now received clearance from the US Food and Drug Administration (FDA) to study UB-VV400, seeking to move the key manufacturing steps inside the patient’s body.

UB-VV400 is a CD22-targeted lentiviral vector therapy. After intravenous administration, it is designed to selectively transduce a patient’s T cells, generating CAR-T cells in vivo that can recognize and attack CD22-positive cells. The company says it is the industry’s first known CD22-directed in-vivo CAR-T candidate to enter a US clinical trial; this “first” designation is currently based primarily on the company’s statement and is not an official FDA determination of the chronological order of similar technologies.

CD22 is primarily expressed on the surface of normal and malignant B cells and differs from CD19, which is targeted by several existing CAR-T therapies. The purpose of selecting another antigen is to provide an alternative route of attack for patients who relapse after receiving CD19-directed therapy and whose tumors have lost or reduced CD19 expression. However, CD22 is also present on normal B cells, so in addition to efficacy, B-cell depletion and the associated infection risks will be important components of the safety assessment.

A research abstract published by the European Hematology Association indicates that UB-VV400 uses a third-generation, self-inactivating, replication-incompetent lentiviral vector, with surface engineering intended to promote T-cell adhesion, activation, and transduction. The vector also incorporates a cytokine receptor system that can be activated by rapamycin, with the aim of providing survival and expansion signals to transduced cells. Therefore, in this study, rapamycin is used not only as a conventional immunosuppressive drug but also as a switch to regulate the engineered cells.

The Phase 1/2 open-label trial, named VIBRANT-1, will enroll adults with CD22-positive relapsed or refractory large B-cell lymphoma and mantle cell lymphoma, including some patients whose disease continued to worsen after prior CAR-T treatment. Phase 1 will gradually escalate the dose in separate disease cohorts to determine safety, the highest tolerable or administrable dose, and the recommended Phase 2 dose. Phase 2 will use overall response rate as the primary efficacy endpoint while also tracking duration of response, pharmacokinetics, and pharmacodynamics.

Umoja expects to dose the first patient in the United States in the third quarter of 2026 and plans to release preliminary data from an investigator-initiated trial in China in the second half of the same year. Currently available public information has not yet provided the number of patients, response rates, duration of response, or complete adverse-event data, so the early clinical activity and safety profile claimed by the company still cannot be independently assessed.

The significance of this IND clearance is that UB-VV400 is authorized to test its concept in human trials in the United States; it does not mean that the FDA has confirmed the therapy is effective or approved it for marketing. Whether in-vivo gene delivery can precisely target T cells and avoid transducing unintended cells, and whether the number and persistence of the resulting CAR-T cells can be controlled, are all more prominent concerns than with conventional ex vivo manufacturing. Only the first clinical data will show whether the concept of simplifying the manufacturing process can translate into acceptable risks and antitumor effects.

References

  1. Umoja Biopharma
  2. European Hematology Association / HemaSphere